early-phase
No description yet: the sentence for this tag has not been written. 7 records carry it: 7 people.
Related tags
7 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Antoine Italiano Head of Early-Phase Trials and Sarcoma Unit, Institut Bergonié, Bordeaux · Institut Bergonié Bordeaux oncologist who led CABONE, the trial that showed cabozantinib shrinks or stabilises osteosarcoma and Ewing sarcoma after standard treatment has failed. | Osteosarcoma, Ewing sarcoma, Sarcomas | none | sarcoma, trialist | ||
Daniel D. Von Hoff Distinguished Professor, Translational Genomics Research Institute (TGen); Physician-in-Chief, HonorHealth Research Institute · Translational Genomics Research Institute (TGen) Led the MPACT trial of nab-paclitaxel plus gemcitabine and has run more first-in-human cancer trials than almost anyone. | Pancreatic ductal adenocarcinoma | none | pancreatic, drug-development | ||
Eytan M. Stein Chief, Leukemia Service, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led the enasidenib and revumenib trials that brought IDH2 and menin inhibitors to acute leukaemia. | Acute myeloid leukaemia, Acute lymphoblastic leukaemia | none | aml, menin, idh | ||
Jason J. Luke Director, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center · UPMC Hillman Cancer Center Led KEYNOTE-716, which extended adjuvant pembrolizumab to high-risk stage II melanoma. | Melanoma | none | melanoma, adjuvant | ||
Komal Jhaveri Section Head, Endocrine Therapy Research, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Leads the next wave of endocrine therapy: oral SERDs like imlunestrant and the PI3K inhibitor inavolisib. | HR-positive / HER2-negative breast cancer | none | breast, endocrine | ||
Razelle Kurzrock Professor of Medicine, Medical College of Wisconsin; Linda T. and John A. Mellowes Endowed Chair in Precision Oncology · Medical College of Wisconsin Cancer Center Precision oncology pioneer who showed that matching drugs to each patient's mutations, in combination, improves outcomes. | none | none | precision-oncology, n-of-1 | ||
Vivek Subbiah Medical oncologist and Chief of Early-Phase Drug Development, Sarah Cannon Research Institute Early-phase trialist who led the study showing dabrafenib and trametinib work in BRAF-mutant anaplastic thyroid cancer, the first approved treatment for that disease, and many of the RET inhibitor trials. | Anaplastic thyroid cancer, Thyroid cancer, Medullary thyroid cancer | none | thyroid, targeted-therapy, trialist |
